FDA Grants Priority Review for Liso-Cel in B-cell Lymphoma By Sam | February 24, 2020 Liso-cel was previously granted breakthrough therapy and regenerative medicine advanced therapy designations. Source: Devices & Diagnostics Letter Posted in Devices & Diagnostics Letter